4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. - Test2 - elhamkhani - TriplyDB

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

http://www.wikidata.org/entity/Q34013829

about

Single cell analysis of drug distribution by intravital imaging BRCAness: finding the Achilles heel in ovarian cancer High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Trial watch - inhibiting PARP enzymes for anticancer therapy Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors Precision targeted therapy of ovarian cancer Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma PARP inhibition: PARP1 and beyond Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors Single cell resolution in vivo imaging of DNA damage following PARP inhibition A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors Imaging the DNA damage response with PET and SPECT Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Red Si-rhodamine drug conjugates enable imaging in GFP cells.The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes.Removal of shelterin reveals the telomere end-protection problem.PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling.Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.Depletion of the central metabolite NAD leads to oncosis-mediated cell death.Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.An update on PARP inhibitors for the treatment of cancer Targeting the homologous recombination pathway by small molecule modulators

P2860

Q21133568-7B4154EC-9F20-4621-BDC7-127F728E1D72 Q24630872-53A222CF-FFC6-4BC7-9B94-CB4C00C3FB8A Q24644255-4175E461-AA48-4172-BAFC-C17AB9F4FBBE Q26745673-85B0D645-A5E0-403D-9BD4-CA1B628ABACC Q26825474-882D79DB-A99B-438F-AE87-682B54926168 Q27684215-983CB2B4-E194-44D5-9971-DB2F194F3D39 Q27684311-52F752C4-CA8F-44B2-9DEE-EE218DD77E2F Q28078658-C60F7C74-248C-42E7-BA5C-9A00037770AD Q28480882-E456FE8B-31EC-4E7D-A936-B624BEDBE729 Q28483989-C949BA7B-DDF3-43D7-BE2D-EB5B9613D8FB Q28538059-82F11073-6CFE-4F21-893B-FEF639FFE90D Q28550512-D247EA07-A6EA-4C74-BA97-2C0CD121C6AE Q29619617-793C4917-9117-485A-BB06-3E720A08F038 Q30252194-647111BD-1BC7-4440-BA71-9098C3732F74 Q30575798-67546929-E18B-40C7-A961-B6456D88E99D Q30650918-55FA53E2-6A19-4A0A-AD1D-70D106CE2182 Q33394173-DD426140-C0CF-46DC-81FD-B2B23FC42E50 Q33395375-CA422E10-C553-4565-9F02-5B63E8D6E48E Q33557916-087546BD-0D4B-454D-B5CC-187D251D7BA5 Q33575946-5DB8C2D2-8907-444A-8FA8-D90179147241 Q33581909-091D8A23-759A-4B11-8302-2E34644B4A18 Q33607384-76D4A81C-2378-4FF3-B2A7-4FB20B131C42 Q33617922-1BDF65C1-0FB8-4DC2-8A26-7A80DAC10C31 Q33640944-E937B432-4619-433D-B870-C92523C1DD2B Q33874466-094580ED-ED5E-4FD6-BF2F-8811CC7B4170 Q34092219-42405B84-2168-4CEF-A82E-11C6D86194F3 Q34272638-9E23FF1A-7190-404A-82A7-C7742A402505 Q34346449-8901EBF7-2FD2-4F96-8242-0CE8776E2BDE Q34358623-9CC67B6B-21D3-49BE-B5CF-F4C0ED3B66DD Q34441033-4BC1280D-0225-40DC-8C3D-9D59B7A78127 Q34592125-3A9C2C6D-62BD-4704-B86F-6D66DB62D2DF Q34644116-36DF7ECD-6206-475A-8E59-FF5AE2430452 Q34737798-D759FC22-046C-49FA-833D-4E86E836D179 Q34924205-B05BC0FD-BE15-45A9-84DB-F8177C37AA45 Q34924914-F3FACE29-E8E3-4510-A6A5-96CAF6C92196 Q34978267-EC9EF845-CA6D-41CA-8787-C1F4FA40448A Q34993640-A942C226-AE67-462E-98E2-7872D40EA6EE Q35111994-59D1A8B9-77F8-4B91-82DC-0B452E7AD87B Q35142718-ACEB4C27-04C2-4054-9C14-5724DA428368 Q35173054-3F1998F0-0384-432B-ADE6-043BE1770B00

P2860

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

http://www.wikidata.org/entity/Q34013829

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@ast

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@en

type

label

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@ast

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@en

prefLabel

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@ast

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@en

P1433

Q34013829-F7294550-02D0-4B3E-BE83-A6CA41CD4956

P1476

Q34013829-6FC3FBBE-9D63-48AF-BF6A-0C566DDA8159

P2093

Q34013829-28C957CD-8F14-496B-BF65-DA89142B54FF

Q34013829-3F6DDB85-43B7-4C08-857A-CE719D392081

Q34013829-4407DF5E-D252-4F4E-8D8F-C7A903B3E10E

Q34013829-4544E25F-8357-4F21-93B6-49CCEB5439F8

Q34013829-4CC0B868-7C89-4B50-80A4-E2F70740B6C1

Q34013829-4F7B2F64-B9DD-483A-806A-E722668F3F62

Q34013829-51F8285D-95BA-40AE-A08B-8CF4E4948608

Q34013829-57268147-AAE9-4592-90A6-7EA824C88B75

Q34013829-5D2F9DFC-544B-443C-BC19-E0C957555785

Q34013829-6E0C9E08-FE9B-46F1-B235-450DE82A126D

P304

Q34013829-84F3AE81-26C2-442E-A1BA-BFE4234B2555

P31

Q34013829-F1741FFA-4B27-4200-B407-866E1622CB37

P356

Q34013829-9341CBF2-D5E1-44CB-A5E2-B6F7E34285FA

P407

Q34013829-74006C1D-67C6-4E5C-8844-7BD094689DD3

P433

Q34013829-F3433FA5-BB90-4ABD-919F-658BFCB618D6

P478

Q34013829-4C52FA9A-91E6-492C-A3C6-1B16FE93B3A7

P577

Q34013829-086A3B40-935B-479F-978C-6A07CF9532A6

P698

Q34013829-A769AD55-228E-4E23-A745-481A9C39AF1D

P921

Q34013829-3A1646A7-9240-4FBB-B131-C5400353B811

P356

P1433

Journal of Medicinal Chemistry

P1476

4-[3-(4-cyclopropanecarbonylpi ...... poly(ADP-ribose) polymerase-1.

@en

P2093

Aaron Cranston

http://www.w3.org/2001/XMLSchema#string

Alan Lau

http://www.w3.org/2001/XMLSchema#string

Charlotte Knights

http://www.w3.org/2001/XMLSchema#string

Claire Adcock

http://www.w3.org/2001/XMLSchema#string

Frank Kerrigan

http://www.w3.org/2001/XMLSchema#string

Graeme C M Smith

http://www.w3.org/2001/XMLSchema#string

Hashim Javaid

http://www.w3.org/2001/XMLSchema#string

Ian T W Matthews

http://www.w3.org/2001/XMLSchema#string

Jan Drzewiecki

http://www.w3.org/2001/XMLSchema#string

Keith A Menear

http://www.w3.org/2001/XMLSchema#string

P304

6581-6591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM8001263

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18800822

http://www.w3.org/2001/XMLSchema#string

P921